US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Fidelity MSCI Health Care Index ETF
(NY:
FHLC
)
81.29
+0.69 (+0.86%)
Official Closing Price
Updated: 8:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fidelity MSCI Health Care Index ETF
< Previous
1
2
Next >
Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech
↗
October 05, 2026
Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance.
Via
The Motley Fool
Topics
ETFs
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?
↗
September 24, 2026
VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility.
Via
The Motley Fool
Topics
ETFs
Does Fidelity or iShares Have the Better Healthcare ETF For Investors Seeking Broad Exposure?
↗
September 16, 2026
FHLC delivered 24% returns over one year with a 0.08% expense ratio, while IXJ offers global diversification but trails on performance and costs more to own.
Via
The Motley Fool
Topics
ETFs
FDA To Ease Review Process For Life-Saving Gene-Editing Therapies: Report
↗
October 31, 2025
Via
Stocktwits
BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study
↗
September 10, 2025
Via
Stocktwits
BioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret Later
↗
August 27, 2025
Via
Stocktwits
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?
↗
September 10, 2026
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
Via
The Motley Fool
Topics
ETFs
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?
↗
September 10, 2026
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
Via
The Motley Fool
Topics
ETFs
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ
↗
September 02, 2026
Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.
Via
The Motley Fool
Topics
ETFs
Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus
↗
August 26, 2026
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
Via
The Motley Fool
Topics
ETFs
FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors?
↗
August 23, 2026
Here's how Invesco's concentrated pharma play compares to Fidelity's diversified approach to healthcare stocks.
Via
The Motley Fool
Topics
ETFs
Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?
↗
August 14, 2026
Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.
Via
The Motley Fool
Topics
ETFs
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or Simplify's Actively Managed PINK?
↗
August 13, 2026
Fidelity's broad, low-cost index approach goes head-to-head with an actively managed, mission-driven healthcare fund.
Via
The Motley Fool
Topics
ETFs
Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit?
↗
August 01, 2026
FHLC holds 334 positions versus IYH's 100, yet both delivered similar five-year returns despite their structural differences.
Via
The Motley Fool
Topics
ETFs
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?
↗
July 31, 2026
FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.
Via
The Motley Fool
Topics
ETFs
XLV vs FHLC: Which Healthcare ETF Fits Your Portfolio?
↗
July 27, 2026
State Street's concentrated 60-stock approach outpaced Fidelity's broader 365-holding fund over five years, though both charge identical 0.08% fees.
Via
The Motley Fool
Topics
ETFs
Which Healthcare ETF Is the Better Buy: Vanguard's VHT or Fidelity's FHLC?
↗
July 23, 2026
One basis point separates these two healthcare funds. Here is why the bigger decision is whether to own healthcare at all.
Via
The Motley Fool
Topics
ETFs
Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?
↗
July 05, 2026
One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility.
Via
The Motley Fool
Topics
ETFs
FHLC vs. BBH: Which Healthcare ETF Is the Better Buy?
↗
July 04, 2026
Compare fees, diversification, and risk between these two leading healthcare ETFs.
Via
The Motley Fool
Topics
ETFs
Fidelity (FHLC) vs. iShares (IXJ): Which Healthcare ETF Delivers Better Value?
↗
June 26, 2026
Compare global reach to domestic focus as these two funds reveal key differences in cost, risk, and portfolio makeup for healthcare investors.
Via
The Motley Fool
Topics
ETFs
FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026?
↗
June 16, 2026
Portfolio size and stock selection set these healthcare ETFs apart and help shape their risk and return profiles.
Via
The Motley Fool
Topics
ETFs
Adding a Healthcare Stock to Your Portfolio? FHLC Offers Broad Coverage While PPH Leads in Returns.
↗
June 02, 2026
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.
Via
The Motley Fool
Topics
ETFs
Better Health Care ETF: Fidelity's FHLC vs. State Street's XLV
↗
May 24, 2026
Expense ratios match, but portfolio breadth, yield, and stock concentration set these two healthcare ETFs apart for investors seeking sector exposure.
Via
The Motley Fool
Topics
ETFs
Federal Judge Halts National Institutes of Health's Grant Policy Overhaul Citing Legal Violations
↗
March 06, 2025
A federal court blocked NIH's policy capping indirect cost rates on research grants, ruling it unlawful. The decision safeguards billions in funding and ongoing clinical trials.
Via
Benzinga
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
↗
February 24, 2025
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.
Via
Benzinga
ETFs In Focus Post UnitedHealth's Mixed Q4 Results
↗
January 18, 2025
UnitedHealth Group, the largest U.S. health insurer, reported mixed fourth-quarter 2024 results. Shares of the stock dropped nearly 6% on the day following the results. This put various ETFs in the...
Via
Talk Markets
Topics
ETFs
Stocks / Equities
What Lies In Store For Healthcare ETFs In Q3 Earnings?
↗
October 27, 2024
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited.
Via
Talk Markets
Topics
ETFs
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
↗
December 29, 2023
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Via
Benzinga
Lab-Developed Tests Under FDA Scrutiny: What It Means For Startups
↗
October 05, 2023
A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups advance various tests to detect diseases sooner and personalize treatments.
Via
Benzinga
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
↗
July 07, 2023
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as...
Via
Benzinga
< Previous
1
2
Next >
